V940-009 (INTerpath-009)

About this trial

Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and can sometimes be removed with surgery. Some people may receive treatment before surgery (called neoadjuvant treatment), such as chemotherapy, immunotherapy, or both. Chemotherapy is medicine that destroys cancer cells or stops them from growing.
Immunotherapy is a treatment that helps the immune system fight cancer. However, the cancer may not respond completely (go away) to neoadjuvant treatment or may come back after surgery.

Researchers want to know if giving V940 and pembrolizumab, the study medicines, after surgery can help prevent the cancer from coming back in people with NSCLC whose tumors did not respond
completely to neoadjuvant treatment. V940 is designed to help a person’s immune system attack their specific cancer. Pembrolizumab is an immunotherapy.

The goal of this study is to learn if people who receive V940 and pembrolizumab after surgery are cancer free longer than people who receive placebo and pembrolizumab. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Patient Profile

About 680 people with NSCLC will be in this study. They will be at least 18 years old and:
• Have NSCLC that can be removed with surgery
• Can receive pembrolizumab and chemotherapy
• Have not had prior treatment for NSCLC
People who have had up to 4 treatments of pembrolizumab and chemotherapy as their neoadjuvant
treatment followed by surgery to remove the NSCLC may be in this study.

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and Tallaght University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	V940-009 (INTerpath-009)
Number:	25-01
Full Title:	A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/​INTerpath-009)

Principal Investigator:	Dr Sinead Noonan
Type:	Industry Sponsored
Sponsor:	Merck Sharp & Dohme LLC
Recruitment Started:	Global: May 2025 Ireland: Sep 2025

Global Recruitment Target:
Ireland Recruitment Target:	15